[1]张国明,田娅.阿柏西普在眼科疾病治疗中的应用[J].眼科新进展,2020,40(1):001-5.[doi:10.13389/j.cnki.rao.2020.0001]
　ZHANG Guoming,TIAN Ya.Advances in application of Aflibercept for treatment of ocular diseases[J].Recent Advances in Ophthalmology,2020,40(1):001-5.[doi:10.13389/j.cnki.rao.2020.0001]
点击复制

阿柏西普在眼科疾病治疗中的应用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年1期
页码:
001-5
栏目:
述评
出版日期:
2020-01-05

文章信息/Info

Title:
Advances in application of Aflibercept for treatment of ocular diseases
文章编号:
20200101
作者:
张国明; 田娅
518040　广东省深圳市，暨南大学第二临床学院深圳市眼科医院、深圳大学眼视光学院（张国明，田娅）；550004　贵州省贵阳市，贵州医科大学（田娅）
Author(s):
ZHANG Guoming1; TIAN Ya2
1.Shenzhen Eye Hospital,the Second Clinical College of Jinan University Shenzhen Eye Hospital,the School of Optometry & Ophthalmology of Shenzhen University,Shenzhen 518040,Guangdong Province,China
2.Guizhou Medical University,Guiyang 550004,Guizhou Province,China
关键词:
阿柏西普; 血管内皮生长因子; 眼科
Keywords:
Aflibercept; vascular endothelial growth factor; ophthalmology
分类号:
R77
DOI:
10.13389/j.cnki.rao.2020.0001
文献标志码:
A
摘要:
阿柏西普是一种与血管内皮生长因子-A、B及胎盘生长因子特异性结合的人源化重组融合蛋白，其通过降低血管内皮通透性进而抑制新生血管生成，在病理性血管形成过程中扮演重要角色。近年来，该药在医学领域的应用范围不断扩大，在结直肠癌、卵巢癌、糖尿病性黄斑水肿、老年性黄斑变性、视网膜静脉阻塞及早产儿视网膜病变等治疗中均被广泛应用，并取得较好效果。本文旨在综述阿柏西普的药理学特点及其在眼科疾病中的应用现状、治疗优势，为后续药物研究和临床应用提供更多的治疗策略。
Abstract:
Aflibercept is a humanized recombinant fusion protein that specifically binds to vascular endothelial growth factor-A，B and placental growth factor.It plays an important role in pathological angiogenesis by reducing vascular endothelial permeability and thereby inhibiting neovascularization.In recent years，Aflibercept has been widely used in the treatment of colorectal cancer，ovarian cancer，diabetic macular edema，age-related macular degeneration，retinal vein occlusion and retinopathy of prematurity，and achieved good results.The article has reviewed the pharmacological characteristics of Aflibercept and its current application status and therapeutic advantages in ocular diseases，so as to provide more treatment strategies for subsequent drug research and clinical drug selection.

参考文献/References:

［1］　AVERY R L，CASTELLARIN A A，STEINLE N C，DHOOT D S，PIERAMICI D J，SEE R，et al.Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept，bevacizumab，and ranibizumab［J］.Retina，2017，37（10）：1847-1858.
［2］　PAPADOPOULOS Z.Aflibercept：A review of its effect on the treatment of exudative age-related macular degeneration［J］.Eur J Ophthalmol，2019，29（4）：368-378.
［3］　何薇，黄棋，余曦，吕红彬.浅谈在糖尿病性视网膜病变中调节血管内皮生长因子产生的信号通路［J］.中华眼科医学杂志（电子版），2018，8（5）：235-240.
HE W，HUANG Q，YU X，LV H B.Exploring the signal pathway regulating vascular endothelial growth factor production in diabetic retinopathy［J］.Chin J Ophthalmol Med（Electron Edit），2018，8（5）：235-240.
［4］　STEWART M W.Aflibercept （VEGF Trap-eye）：the newest anti-VEGF drug［J］.Br J Ophthalmol，2012，96（9）：1157-1158.
［5］　雷琦峰，蔡维.阿柏西普对体外培养的视网膜Müller细胞膜离子通道的影响［J］.国际眼科杂志，2019，19（4）：547-550.
LEI Q F，CAI W.Effects of Aflibercept on ion channel of retinal Müller cell membrane cultured in vitro［J］.Int Eye Sci，2019，19（4）：547-550.
［6］　JOANA M，JOAO P C，SARA V P，ARMINDA N，LUIS A P，CANDIDA T T.Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies：Current research and future perspectives［J］.Cytokine Growth Factor Rev，2018，39：102-115.
［7］　TAPAN B，ANITA K.Exploring the various aspects of the pathological role of vascular endothelial growth factor （VEGF） in diabetic retinopathy［J］.Pharmacol Res，2015，99：137-148.
［8］　CAMPA C，ALIVERNINI G，BOLLETTA E，PARODI M B，PERRI P.Anti-VEGF therapy for retinal vein occlusions［J］.Curr Drug Targets，2016，17（3）：328-336.
［9］　KANDASAMY Y，HARTLEY L，RUDD D，SMITH R.The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants：a systematic review［J］.Br J Ophthalmol，2017，101（1）：21-24.
［10］　SARWAR S，CLEARFIELD E，SOLIMAN M K，SADIQ M A，BALDWIN A J，HANOUT M，et al.Aflibercept for neovascular age-related macular degeneration［J］.Cochrane Database Syst Rev，2016，2：CD011346.
［11］　GHEORGHE A，MAHDI L，MUSAT O.Age-related macular degeneration［J］.Rom J Ophthalmol，2015，59（2）：74-77.
［12］　WASEEM M A，SANAA A Y.Recent developments in age-related macular degeneration：a review［J］.Clin Interv Aging，2017，12：1313-1330.
［13］　BLACK J R，CLARKlark S J.Age-related macular degeneration：genome-wide association studies to translation［J］.Genet Med，2016，18（4）：283-289.
［14］　BA J，PENG R S，XU D，LI Y H，SHI H，WANG Q，et al.Intravitreal anti-VEGF injections for treating wet age-related macular degeneration：a systematic review and meta-analysis［J］.Drug Des Devel Ther，2015，28（9）：5397-5405.
［15］　DAVID M B，JEFFREY S H，THOMAS C，MATTHEW B，PREMA A，GEORGE Y，et al.Primary endpoint results of a phase Ⅱ study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration［J］.Ophthalmology，2011，118（6）：1089-1097.
［16］　邹洪强，田洪芹，张艳平，李荣欣.阿柏西普治疗眼底血管性疾病的临床研究新进展［J］.眼科新进展，2017，37（9）：894-897.
ZOU H Q，TIAN H Q，ZHANG Y P，LI R X.Recent advances in clinical research on aflibercept treating fundus vascular diseases［J］.Rec Adv Ophthalmol，2017，37（9）：894-897.
［17］　BRAIMAH I Z，AGARWAL K，MANSOUR A，CHHABLANI J.One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration［J］.Br J Ophthalmol，2018，102（1）：91-96.
［18］　KIM J H，LEE T G，CHANG Y S，KIM C G，CHO S W.Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept：a comparative study［J］.Br J Ophthalmol，2016，100（12）：1634-1639.
［19］　ZHANG J X，LIANG Y，XIE J，LI D，HU Q，LI X S，et al.Conbercept for patients with age-related macular degeneration：a systematic review［J］.BMC Ophthalmol，2018，18，（1）：142.
［20］　CHUNMEI C，HONG L.Clinical observations on the use of new anti-VEGF drug，conbercept，in age-related macular degeneration therapy：a meta-analysis［J］.Clin Interv Aging，2018，13：51-62.
［21］　SCHMIDT E U，GARCIA A J，BANDELLO F，BERG K，CHAKRAVARTHY U，GERENDAS B S，et al.Guidelines for the management of diabetic macular edema by the european society of retina specialists （EURETINA）［J］.Ophthalmologica，2017，237（4）：185-222.
［22］　LUKIC M，WILLIAMS G，SHALCHI Z，SIM D，PATEL P J，KEANE P A，et al.Intravitreal aflibercept for diabetic macular oedema：Moorfields’ real-world 12-month visual acuity and anatomical outcomes［J］.Eur J Ophthalmol，2019，26：1120672119833270.
［23］　SHIMIZU N，OSHITARI T，TATSUMI T，TAKATSUNA Y，ARAI M，SATO E，et al.Comparisons of efficacy of Intravitreal Aflibercept and Ranibizumab in eyes with diabetic macular edema［J］.Biomed Res Int，2017，2017：1747108.
［24］　IBRAHIM W S，ELDALY Z H，SALEH M G，RATEB M F，ALDOGHAIMY A H.Switching to Aflibercept in diabetic macular edema after unsatisfactory response to other anti-vascular endothelial growth factor drugs［J］.Korean J Ophthalmol，2019，33（2）：122-130.
［25］　CAI S W，YANG Q H，LI X R，ZHANG Y.The efficacy and safety of aflibercept and conbercept in diabetic macular edema［J］.Drug Des Devel Ther，2018，12：3471-3483.
［26］　MACDONALD D A，MARTIN J，MUTHUSAMY K K，LUO J K，PYLES E，RAFIQUE A，et al.Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes［J］.Angiogenesis，2016，19（3）：389-406.
［27］　PIERRU A，GIRMENS J F，HERON E，PAQUES M.Retinal vein occlusions［J］.J Fr Ophtalmol，2017，40（8）：696-705.
［28］　LOLA A，COLIN B.Cost-effectiveness of ranibizumab versus aflflibercept for macular edema secondary to branch retinal vein occlusion：A UK healthcare perspective［J］.Adv Ther，2016，33（1）：116-128.
［29］　KIDA T.Mystery of retinal vein occlusion：vasoactivity of the vein and possible involvement of endothelin-1［J］.Biomed Res Int，2017，2017：4816527.
［30］　ASHRAF M，SOUKA A A，SINGH R P.Central retinal vein occlusion：modifying current treatment protocols［J］.Eye （Lond），2016，30（4）：505-514.
［31］　WANG J K，SU P Y，HSU Y R，CHEN Y J，CHEN F T，TSENG Y Y.Comparison of the efficacy of intravitreal aflibercept and Bevacizumab for macular edema secondary to branch retinal vein occlusion［J］.J Ophthalmol，2016，2016：8421940.
［32］　LOTFY A，SOLAIMAN K A M，ABDELRAHMAN A，SAMIR A.Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion［J］.Retina，2018，38（9）：1795-1800.
［33］　SANGROONGRUANGSRI S，RATANAPAKORN T，WU O，ANOTHAISINTAWEE T，CHAIKLEDKAEW U.Comparative efficacy of bevacizumab，ranibizumab，and aflibercept for treatment of macular edema secondary to retinal vein occlusion：a systematic review and network meta-analysis［J］.Expert Rev Clin Phar，2018，11（9）：903-916.
［34］　CAMPOCHIARO P A，CLARK W L，BOYER D S，HEIER J S，BROWN D M，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion：the 24-week results of the VIBRANT study［J］.Ophthalmology，2015，122（3）：538- 544.
［35］　CLARK W L，BOYER D S，HEIER J S，BROWN D M，HALLER J A，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion：52-week results of the VIBRANT Study［J］.Ophthalmology，2016，123（2）：330-336.
［36］　GILBERT C.Retinopathy of prematurity：a global perspective of the epidemics，population of babies at risk and implications for control［J］.Early Hum Dev，2008，84（2）：77-82.
［37］　BASHINSKY A L.Retinopathy of prematurity［J］.N C Med J，2017，78（2）：124-128.
［38］　SMITH L E.Pathogenesis of retinopathy of prematurity［J］.Semin Neonatol，2003，8（6）：469-473.
［39］　李丹，董宇.早产儿视网膜病变发病基础及抗VEGF药物治疗研究进展［J］.眼科新进展，2016，36（4）：396-400.
LI D，DONG Y.Research progress on foundation and anti-VEGF drug therapy of retinopathy of prematurity［J］.Rec Adv Ophthalmol，2016，36（4）：396-400.
［40］　VEDANTHAM V.Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity［J］.Indian J Ophthalmol，2019，67（6）：884-888.
［41］　VURAL A，PERENTE I ·，ONUR I * U，ERIS E，SEYMEN Z，HERGUNSEL G O，et al.Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography［J］.Int Ophthalmol，2019，39（10）：2161-2169.
［42］　SUKGEN E A，KOCLUK Y.Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity［J］.Graefes Arch Clin Exp Ophthalmol，2019，257（1）：49-55.
［43］　ZHANG Y，HAN Q，RU Y，BO Q，WEI R H.Anti-VEGF treatment for myopic choroid neovascularization：from molecular characterization to update on clinical application［J］.Drug Des Devel Ther，2015，9：3413-3421.
［44］　IKUNO Y，OHNO-MATSUI K，WONG T Y，KOROBELNIK J，VITTI R，LI T，et al.Intravitreal Aflibercept injection in patients with myopic choroidal neovascularization：The MYRROR study［J］.Ophthalmology，2015，122（6）：1220-1227.
［45］　ZHOU Y，YANG S，YUAN Y，SONG M，KUANG F，LIU K，et al.Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy：a post-hoc analysis［J］.Eye （Lond），2019，［Epub ahead of print］.
［46］　STEWART M W.Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration：focus on aflibercept［J］.Clin Ophthalmol，2012，6：1175-1186.
［47］　SCOTT I U，VANVELDHUISEN P C，IPp M S，BLODI B A，ODEN N L，AWH C C，et al.Effect of Bevacizumab vs Aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion：The SCORE2 randomized clinical trial［J］.JAMA，2017，317（20）：2072-2087.
［48］　徐蓓，赵志刚，刘桂英.治疗黄斑疾病的新型血管内皮生长因子抑制剂阿柏西普［J］.中国新药杂志，2013，22（6）：617-619.
XU B，ZHAO Z G，LIU G Y.Aflibercept，a new VEGF inhibitors for macular disease［J］.Chin J New Drug，2013，22（6）：617-619.

相似文献/References:

[1]程文武 江萍 席祖莲 张汉武 訾世莉 聂军 董彩虹.蛹虫草提取物抑制大鼠角膜新生血管的实验研究[J].眼科新进展,2012,32(5):000.
[2]于静 张明昌.苦参碱对大鼠角膜新生血管的抑制作用[J].眼科新进展,2012,32(6):000.
[3]吴正正 严京 接传红 高健生 陈皆春 宋剑涛.密蒙花方对缺氧状态下脐静脉血管内皮细胞 VEGF-VEGFR 信号转导通路的影响[J].眼科新进展,2012,32(7):000.
[4]庞霞 曲蕴慧 马跃伟 张效房 董敬民 高冬玲.去整合素金属蛋白酶9和血管内皮生长因子蛋白在眼部恶性黑色素瘤中的表达[J].眼科新进展,2012,32(7):000.
[5]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[8]曾莉 常以力 邵毅.血管内皮生长因子反义寡脱氧核苷酸联合血管生成素-1对糖尿病视网膜病变大鼠视网膜血管渗漏及新生血管生成的影响[J].眼科新进展,2012,32(10):000.
[9]兰兰 惠延年 曾光伟.血管生成素-1对糖尿病大鼠视网膜微血管病变、基质金属蛋白酶和血管内皮生长因子的抑制作用[J].眼科新进展,2012,32(10):000.
[10]谢明捷 吕红彬 何跃 赵春会.炎症因子与糖尿病视网膜病变相关性研究进展[J].眼科新进展,2012,32(10):000.
[11]邹洪强,田洪芹,张艳平,等.阿柏西普治疗眼底血管性疾病的临床研究新进展[J].眼科新进展,2017,37(9):894.[doi:10.13389/j.cnki.rao.2017.0227]
　ZOU Hong-Qiang,TIAN Hong-Qin,ZHANG Yan-Ping,et al.Recent advances in clinical research on aflibercept treating fundus vascular diseases[J].Recent Advances in Ophthalmology,2017,37(1):894.[doi:10.13389/j.cnki.rao.2017.0227]
[12]卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效[J].眼科新进展,2019,39(4):340.[doi:10.13389/j.cnki.rao.2019.0076]
　LU Qian-Yi.Intravitreal aflibercept injection for the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(1):340.[doi:10.13389/j.cnki.rao.2019.0076]

备注/Memo

备注/Memo:
深圳市学科布局项目（编号：JCYJ20170817112542555）
更新日期/Last Update: 2020-01-05